Proteasome inhibition and its therapeutic potential in multiple myeloma

Ajai Chari 1
Amitabha Mazumder 2
Sundar Jagannath 1

1 Mount Sinai School of Medicine, New York, NY, USA; 2 New York University School of Medicine, New York, NY, USA

Abstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an unprecedented eight years. In the wake of this rapid approval arose a large number of questions about its mechanism of action and toxicity as well as its ultimate role in the treatment of this disease. In this article, we briefly review the preclinical and clinical development of the drug as the underpinning for a systematic review of the large number of clinical trials that are beginning to shed some light on the full therapeutic potential of bortezomib in myeloma. We conclude with our current understanding of the mechanism of action of this agent and a discussion of the novel proteasome inhibitors under development, as it will be progress in these areas that will ultimately determine the true potential of proteasome inhibition in myeloma.

Keywords: bortezomib, multiple myeloma

The proteasome

The proteasome is a large, hollow cylindrical multi-enzymatic complex that is present in both the cytoplasm and the nucleus of all eukaryotic cells. It is necessary for the degradation of intracellular proteins in eukaryotic cells whereas extracellular/transmembrane proteins are typically degraded by the aggresome/lysosomal pathway. The formation of the 26S proteasome occurs in an ATP dependent fashion, when a 20S catalytic core is capped by a 19S regulatory subunit at both ends (see Figure 1A). The lysine residues of those proteins targeted for degradation are covalently modified with a polyubquitin protein chain, with each ubiquitin tag consisting of a 76 amino acid polypeptide. The ubiquitin chain is recognized by the lid-like structure of the 19S subunit and then removed. The target protein is then denatured in an energy dependent manner by the 6 ATPases at the base of the 19S subunit and threaded into the center of the 20S subunit.

As shown in Figure 1B, the 20S subunit is itself comprised of four rings, 2α and 2β subunits. Within the channel at the center, threonine residues of the indicated β units wield catalytic activity comparable to three enzymes: chymotrypsin (β5), trypsin (β2), and post-glutamyl peptide hydrolase (β1).

Proteasome inhibition and its therapeutic potential in multiple myeloma

Biologics: Targets & Therapy downloaded from https://www.dovepress.com/ on 05-Apr-2022
For personal use only.
Preclinical development of bortezomib

In 1993, the company Myogenics was founded by Alfred Goldberg to decrease muscle wasting/cachexia by inhibiting the ubiquitin–proteasome pathway. A team of enzymologists created the first inhibitors of the proteasome: peptide aldehyde analogs of the proteasome’s chymotrypsin-like substrates. Chemists then created a dipeptide boronic acid analog that would eventually come to be known as bortezomib (Figure 2).3

When applied to the National Cancer Institute’s 60-cell line screen, bortezomib demonstrated potent growth inhibition against a broad range of tumor types.5 Importantly, confirmation was also obtained that the intended biologic target was being inhibited. Additional studies with human myeloma cell lines and freshly isolated from myeloma patients confirmed that bortezomib not only inhibited tumor proliferation but also induced apoptosis and overcame drug resistance.6

The growth inhibition of bortezomib was extended to the in vivo setting using a human plasmacytoma xenograft mouse model. Relative to controls, bortezomib treatment resulted in improved overall survival.7 A fluorogenic pharmacodynamic assay was developed to measure the relative chymotryptic and tryptic activities of the proteasome in peripheral blood mononuclear cells.8 This assay showed that bortezomib-mediated inhibition of the chymotrypsin-like activity of the 26S mammalian proteasome (Figure 1B) was dose-dependent and reversible,7 thus helping guide dosing and optimize dose escalation in phase I studies.

Clinical development of bortezomib – relapsed/refractory multiple myeloma

In a phase I trial among patients with advanced hematological malignancies, bortezomib was noted to have activity in the...
patients with refractory myeloma; among nine patients with multiple myeloma antitumor activity was noted in almost all patients including 1 patient achieving a complete response.4 A subsequent, large, multicenter phase II trial involving 202 patients with relapsed, refractory myeloma yielded a 35% overall response rate which was comprised of a 4% complete remission (CR), 6% near CR, 18% partial remission (PR), and 7% minimal response (MR).5 It was on the basis of this trial in large part, that bortezomib was approved by the United States Food and Drug Administration (FDA) in 2003, thus resulting in a remarkably short 8 years from drug discovery to FDA approval.

The phase III Assessment of Proteasome Inhibition for Extending Remissions (APEX) study compared bortezomib (1.3 mg/m² on days 1, 4, 8, and 11 by intravenous push for eight 3-week cycles) to high dose dexamethasone (40 mg days 1–4, 9–12, and 17–20 orally for four 5-week cycles and then days 1–4 for five 4-week cycles) in 669 patients with relapsed multiple myeloma. The study was halted on interim analysis because bortezomib treatment resulted in higher response rates (38 vs 18%), longer time to progression (6.22 months vs 3.49 months), and improved overall survival. The median time to response was 43 days in both groups.10 In an updated analysis, based on a median follow up of 22 months, the median overall survival was 29.8 vs 23.7 months (P = 0.0272) despite a 62% crossover rate from dexamethasone to bortezomib.11 As shown in Figure 3, a comparison of the Grade 3/4 adverse events in each arm reveals that bortezomib treatment is associated with an increased incidence of thrombocytopenia, neutropenia, peripheral neuropathy, and diarrhea.10 The thrombocytopenia and neuropathy are discussed in further detail below. Despite these toxicities, a prospective comparison of health-related quality of life found improved outcomes with bortezomib.12 Of note, subgroup analysis has also found no difference in safety or efficacy in patients with varying degrees of renal insufficiency.13

Bortezomib therapy also appears to have beneficial effects on the bone. When alkaline phosphatase levels were compared with responders and nonresponders in the APEX study, the most powerful predictor of a response was a 25% increase in alkaline phosphatase at week 6 (P < 0.0001) (Figure 4).14 Laboratory work has confirmed the ability of bortezomib to not only inhibit osteoclast mediated bone destruction, but also directly induce bone formation.15,16 Interestingly, as shown in Figure 4, the increase in alkaline phosphatase was not observed on the dexamethasone arm, even in the responders. This increase has also recently been found to be associated with improved time to progression.17

As the safety and efficacy results for bortezomib monotherapy were accumulating, combination therapy was being explored in the preclinical setting. Hideshima et al found that the growth inhibitory effects of bortezomib and dexamethasone on a myeloma cell line were additive (Figure 5A).6 Ma et al found that the addition of a noncytotoxic dose of bortezomib to chemotherapeutic agents could increase the sensitivity of chemoresistant myeloma cells by 100,000 to 1,000,000-fold without affecting normal hematopoietic cells (Figure 5B).18

<table>
<thead>
<tr>
<th>Adverse events Gr 4</th>
<th>Adverse events ≥ Gr 3</th>
<th>Thrombocytopenia</th>
<th>Neutropenia</th>
<th>Anemia</th>
<th>Peripheral neuropathy</th>
<th>Diarrhea</th>
<th>Fatigue</th>
<th>Dyspnea</th>
<th>Pneumonia</th>
<th>Hyperglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortezomib (n = 332)</td>
<td>Dexamethasone (n = 331)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 3 Grade 3/4 adverse events of bortezomib and dexamethasone in the APEX trial.
The largest published phase III clinical trial combining bortezomib with another chemotherapeutic agent randomized 646 myeloma patients with 2 or more lines of prior therapy to receive either the standard dose/schedule of bortezomib alone or with liposomal doxorubicin (PLD) on Day 4. The combination therapy was associated with a higher incidence of grade 3/4 events 80% vs 64% (due to myelosuppression, constitutional and gastrointestinal symptoms, and hand foot syndrome). There was also no significant difference in response rates. However, the time to progression (9.3 vs 6.5 months, $P=0.000004$) and overall survival at 15 months (76% vs 65%, $P=0.03$) both favored bortezomib with PLD.19

This steroid sparing regimen is an excellent treatment option especially for those patients intolerant of steroids due to psychosis or brittle diabetes.

The proteasome inhibitor bortezomib has now been studied in combination with each of the three other classes of drugs with activity in myeloma: steroids, immunomodulatory agents (IMiDs), and conventional chemotherapeutics (anthracyclines and alkylating agents). For those phase I/II studies with 30 or more evaluable patients, summaries of the recent response data of doublet (Table 1), triplet (Table 2), and multiagent (Table 3) permutations of the four classes of drugs in relapsed/refractory myeloma are shown in the indicated tables.

**Bortezomib in previously untreated multiple myeloma**

The only published phase III study of bortezomib in untreated myeloma is the Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan Prednisone (VISTA) study. In this study, 682 nontransplant eligible patients with untreated myeloma were randomized to receive either melphalan and prednisone alone (MP) or with bortezomib (VMP) at the doses and schedule shown in Figure 6.

Overall response rate for VMP was 71% vs 35% for MP with a very impressive CR rate of 30% vs 4% ($P < 0.001$ for both comparisons). Of note, a 30% CR rate compares very favorably to the CR rates obtained for patients who receive high-dose melphalan chemotherapy with autologous stem cell rescue (for which none of the patients in the VISTA study were eligible). With a median follow up of 16.3 months, the
hazard ratio for overall survival for the VMP group was 0.61 ($P = 0.008$).34

All of the following efficacy outcomes were also significantly better for the VMP group relative to MP: median time to first response (1.4 vs 4.2 months), duration of response (20 vs 13 months), and treatment-free interval (17 months vs 9 months). The improved outcomes were seen in all subgroups, including age >75, creatinine clearance <60, and high risk cytogenetics (translocation (t)(4;14), (t(14,16), or chromosome 17 deletion).34 Of note, the lack of effect of high risk cytogenetics on efficacy with bortezomib-based regimens has been a consistent finding across all front line studies.34–37
Table 1 Clinical trials of bortezomib in doublet-drug combination regimens

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Regimen</th>
<th>n</th>
<th>CR/nCR</th>
<th>ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berenson et al19</td>
<td>I/II</td>
<td>Vel/Mel</td>
<td>46</td>
<td>15%</td>
<td>70%</td>
</tr>
<tr>
<td>Popat et al21</td>
<td>I/II</td>
<td>Vel/Mel ± Dex</td>
<td>53</td>
<td>23%</td>
<td>68%</td>
</tr>
<tr>
<td>Pineda-Roman et al22</td>
<td>I/II</td>
<td>VT ± Dex</td>
<td>85</td>
<td>22%</td>
<td>63%</td>
</tr>
</tbody>
</table>

Abbreviations: n, number of evaluable patients; Cr, complete remission; nCr, near complete remission; ORR, overall response rate; Vel/Mel, velcade, melphalan; VT, velcade, thalidomide.

Table 2 Clinical trials of bortezomib in triplet-drug combination regimens

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Regimen</th>
<th>n/N</th>
<th>Cr/nCr</th>
<th>ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reece et al23</td>
<td>I/II</td>
<td>VCP</td>
<td>37/37</td>
<td>27%</td>
<td>68%</td>
</tr>
<tr>
<td>Kropff et al24</td>
<td>II</td>
<td>VCD</td>
<td>50/54</td>
<td>16%</td>
<td>82%</td>
</tr>
<tr>
<td>Hajek et al25</td>
<td>II</td>
<td>PAD→TD</td>
<td>30/39</td>
<td>70%</td>
<td>90%</td>
</tr>
<tr>
<td>Lee et al26</td>
<td>II</td>
<td>PAD</td>
<td>64/64</td>
<td>25%</td>
<td>67%</td>
</tr>
<tr>
<td>Palumbo et al27</td>
<td>II</td>
<td>VTD</td>
<td>62/24</td>
<td>21%</td>
<td>84%</td>
</tr>
<tr>
<td>Richards et al28</td>
<td>II</td>
<td>VBP</td>
<td>46/46</td>
<td>15%</td>
<td>61%</td>
</tr>
</tbody>
</table>

Abbreviations: n/N, number of evaluable patients/total number of enrolled patients; VCP, bortezomib, cyclophosphamide, prednisone; VCD, bortezomib, cyclophosphamide, dexamethasone; TD, thalidomide, dexamethasone; VBP, bortezomib, bendamustine, prednisone.

Table 3 Clinical trials of bortezomib in multiple drug combination regimens

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Regimen</th>
<th>n</th>
<th>Cr/nCr</th>
<th>ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palumbo et al30</td>
<td>I/II</td>
<td>VMPT</td>
<td>30/30</td>
<td>44%*</td>
<td>67%</td>
</tr>
<tr>
<td>Terpos et al31</td>
<td>II</td>
<td>VMDT</td>
<td>62*</td>
<td>–</td>
<td>66%</td>
</tr>
<tr>
<td>Ciolli et al32</td>
<td>II</td>
<td>VTDD</td>
<td>42/42</td>
<td>52%</td>
<td>74%</td>
</tr>
<tr>
<td>Kim et al33</td>
<td>II</td>
<td>VCTD</td>
<td>56/35</td>
<td>53%</td>
<td>92%</td>
</tr>
</tbody>
</table>

*number of evaluable patients unknown.

Abbreviations: n, number of evaluable patients; Cr, complete remission; nCr, near complete remission; ORR, overall response rate; VMPT, bortezomib, melphalan, prednisone; VMDT, bortezomib, melphalan, dex, thalidomide; VTDD, bortezomib, thalidomide, dex, liposomal doxorubicin; VCTD, bortezomib, cyclophosphamide, thalidomide, dex.

Toxicities ≥ Grade 3 that were higher in the VMP arm included peripheral neuropathy (14 vs 0%), nausea/vomiting/diarrhea, fatigue/asthenia, and zoster. Herpes zoster was observed in 14% of VMP patients vs 4% in MP, but among patients receiving antiviral prophylaxis, the rate was 3%.34

Of note, a recent analysis of varicella zoster virus (VZV) reactivation in the APEX study also found a significantly increased incidence in patients receiving bortezomib relative to dexamethasone 13% vs 5%, P = 0.0002.38 Antiviral prophylaxis is therefore recommended for all myeloma patients receiving bortezomib based regimens. A variety of agents and regimens have been used including acyclovir 400 mg daily, valacyclovir 250 or 500 mg daily, famiclovir 500 mg daily.39,40 Doses should be decreased in the setting of renal insufficiency as the metabolites of these drugs can accumulate and cause profound neuropsychiatric changes.41,42 Finally, the varicella vaccine, which contains live attenuated virus, is not licensed for use in patients with neoplasms affecting the bone marrow or lymphatic systems.43

Additional follow up data presented recently indicated that despite the fact that 43% of MP patients subsequently received bortezomib upon progression, intention to treat analysis still demonstrated increased overall survival for the VMP group. Moreover, there was no difference in response to IMiD-based second line treatments between the two groups.44 The results of the VISTA study therefore demonstrate clearly improved efficacy with VMP without any adverse long term consequences of upfront bortezomib based regimens.

There are also several large phase III studies ongoing evaluating the use of bortezomib as induction therapy prior to stem cell transplantation (see Table 4). The Franchophone Myeloma Intergroup (IFM) 2005-01 study randomized 482 patients to receive either bortezomib-dexamethasone (Vel-Dex) or the traditional VAD. Of the 442 evaluable patients, the CR rates were 10% vs 3%, CR + near CR 19% vs 8%, and ≥ PR 83 vs 66% without any impairment in stem cell harvest. Moreover, the higher quality of responses persisted after the first melphalan 200 mg/m2 followed by autologous stem cell rescue, with CR/near CR rates of 40 vs 22%, P = 0.0001.36 Preliminary data from two other phase III studies comparing bortezomib in combination with doxorubicin and dexamethasone (PAD) to traditional VAD37 and bortezomib, thalidomide, and dexamethasone (VTD) to TD35 also found improved CR/nCR rates (23% vs 9%, P < 0.015 and 55% vs 32%, P < 0.001 respectively) after autologous stem cell transplantation.

These improvements in CR rates after transplant with bortezomib based induction therapies have clinical significance. Two large published phase III studies comparing single vs tandem autologous stem cell transplants in myeloma found that patients who did not achieve a CR/near CR after the first autologous stem cell transplant were the ones that could benefit from a second SCT.48,49 Therefore, the higher CR rates being obtained with novel induction regimens may obviate the need for a second autologous
transplant – with its attendant mortality, morbidity, and cost.

While the details of the various bortezomib based front line regimens are beyond the scope of this review, a summary of the responses noted to date are shown in Table 5. With the understanding that response rates in single/few institution phase II studies are typically higher than those obtained in phase III multi-institutional settings, a regimen that stands out is bortezomib, lenalidomide, and dexamethasone (VRD). With 65 evaluable patients, the combination of bortezomib, lenalidomide, and dexamethasone resulted in a 100% response rate and a 38% CR/nCR rate.50 A caveat of course, is that lenalidomide based induction regimens often result in inadequate stem cell harvests with granulocyte colony stimulating factor (GCSF) mobilization and therefore in inadequate stem cell harvests with granulocyte colony stimulating factor (GCSF) mobilization and therefore require cyclophosphamide or the recently FDA-approved CXCR inhibitor, plerixafor, to ensure adequate stem cell harvests.

**Mechanism of action of bortezomib**

While rational drug design and pharmacodynamic assays identified and confirmed the proteasome as the biologic target, without an understanding of the exact mechanism of action, the full therapeutic potential of proteasome inhibition cannot be realized. Research has focused on three possible themes that will be discussed below: the transcription factor NF-κB, the interaction of the pro-apoptotic factor NOXA and the c-myc oncogene, and finally, the transcription factor x-box binding protein 1 (XBP-1) and the unfolded protein response.

Initial focus was on the impact of bortezomib on NF-κB, which promotes tumor cell survival and proliferation. The inhibitor protein IκB binds NF-κB in the cytoplasm, thereby rendering NF-κB inactive. A variety of cytokines and other cellular stimuli result in the phosphorylation and ubiquitination of IκB by E3 ligase, thus targeting it for proteasome mediated degradation (Figure 7).2

Bortezomib, by blocking the latter process, results in increased availability of IκB to inhibit NF-κB, resulting in the inhibition of tumor cell growth. Gene expression profiling studies in patients with myeloma who responded to bortezomib treatment also highlighted pathways such as NF-κB activity and cell adhesion, thereby confirming pre-clinical studies.69

Additional work by Hideshima et al revealed that bortezomib activation seemed to be dependent on the activation of c-Jun NH2-terminal kinase (JNK) and subsequently caspas-8 and caspase-3 that elicit DNA damage and apoptosis. In parallel, bortezomib was noted to be associated with the up-regulation of p53.70 While these initial studies shed some light on the mechanism of action, it is unclear if the changes observed in NF-κB and JNK are a cause or the result of the death process. Indeed, more recent studies suggest the antitymoma activity of proteasome inhibition is actually p53 independent.71

When myeloma cell lines are exposed to bortezomib, the proapoptotic factor NOXA is induced in a concentration dependent manner accompanied by the activation of caspas. NOXA is also induced by p53 and other transcriptional factors such as hypoxia-inducible factor 1 (HIF-1) and E2F-1, consistent

**Table 4 Summary of phase iii trials in previously untreated MM**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Regimen</th>
<th>N/N</th>
<th>CR/nCR</th>
<th>VGPR</th>
<th>PR</th>
<th>ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFM 2005-01: Harousseau et al36</td>
<td>Vel/Dex (vs VAD)</td>
<td>424/482</td>
<td>19% (vs 8%)</td>
<td>24%</td>
<td>43%</td>
<td>83%</td>
</tr>
<tr>
<td>HOVON-65G/GMMG-H4: Sonneveld et al37</td>
<td>PAD (vs VAD)</td>
<td>300/300</td>
<td>23% (vs 9%)</td>
<td>37%</td>
<td>–</td>
<td>83%</td>
</tr>
<tr>
<td>GEMIMA: Cavo et al38</td>
<td>VTD (vs TD)</td>
<td>460/474</td>
<td>55% (vs 32%)</td>
<td>30%</td>
<td>32%</td>
<td>94%</td>
</tr>
<tr>
<td>PETHMA/GEM: Rosiol et al39</td>
<td>VTD vs (TD vs VBMC/P/MBAD/Vel)</td>
<td>183/190</td>
<td>41% (vs 12% vs 28%)</td>
<td>–</td>
<td>39%</td>
<td>80%</td>
</tr>
<tr>
<td>VISTA: San Miguel et al44</td>
<td>VMP (vs MP)</td>
<td>668/682</td>
<td>30% CR (vs 4%)</td>
<td>N/A</td>
<td>40%</td>
<td>71%</td>
</tr>
<tr>
<td>GEM05MA65: Mateos et al45</td>
<td>VMPT (vs VTP)</td>
<td>206/260</td>
<td>41% (vs 37%)</td>
<td>–</td>
<td>40%</td>
<td>81%</td>
</tr>
<tr>
<td>GEMIMA: Palumbo et al46</td>
<td>VMPT (vs VMP)</td>
<td>354/393</td>
<td>39% CR (vs 21%)</td>
<td>16%</td>
<td>32%</td>
<td>87%</td>
</tr>
</tbody>
</table>

**Abbreviations:** VGPR, very good partial remission; VMP, bortezomib, melphalan, prednisone; MP, melphalan, prednisone; VMPT, bortezomib, melphalan, prednisone, thalidomide; VTP, bortezomib, thalidomide, prednisone; VAD, vincristine, adriamycin, doxorubicin; PAD, bortezomib, doxorubicin, dexamethasone; VTD, velcade, thalidomide, dexamethasone; TD, thalidomide, dexamethasone; VBMC/P, BCNU, vincristine, melphalan, prednisone; VBAD, vincristine, BCNU, doxorubicin, dexamethasone.
Table 5  Phase I/II and II combination trials in untreated myeloma

<table>
<thead>
<tr>
<th>Trial</th>
<th>Regimen</th>
<th>n/N</th>
<th>CR/nCR</th>
<th>VGPR</th>
<th>PR</th>
<th>ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harousseau et al51</td>
<td>Vel/Dex</td>
<td>48/52</td>
<td>21% CR</td>
<td>10%</td>
<td>35%</td>
<td>67%</td>
</tr>
<tr>
<td>Corso et al52</td>
<td></td>
<td>54/54</td>
<td>50%</td>
<td>20%</td>
<td>16%</td>
<td>86%</td>
</tr>
<tr>
<td>Rosinol et al53</td>
<td>Vel alternating with Dex</td>
<td>40/40</td>
<td>13% CR</td>
<td>10%</td>
<td>43%</td>
<td>65%</td>
</tr>
<tr>
<td>Jagannath et al54</td>
<td>Vel ± Dex</td>
<td>49/49</td>
<td>18%</td>
<td>20%</td>
<td>49%</td>
<td>88%</td>
</tr>
<tr>
<td>Orlowski et al55</td>
<td>Vel ± PLD</td>
<td>29/63</td>
<td>28%</td>
<td>–</td>
<td>52%</td>
<td>79%</td>
</tr>
<tr>
<td>Jakubowiak et al56</td>
<td>VDD</td>
<td>30/30</td>
<td>40% CR</td>
<td>23%</td>
<td>30%</td>
<td>93%</td>
</tr>
<tr>
<td>Palumbo et al57</td>
<td></td>
<td>102/102</td>
<td>13% CR</td>
<td>47%</td>
<td>36%</td>
<td>96%</td>
</tr>
<tr>
<td>Belch et al58</td>
<td></td>
<td>50/50</td>
<td>18%</td>
<td>–</td>
<td>60%</td>
<td>78%</td>
</tr>
<tr>
<td>Landau et al59</td>
<td>VDD → TD</td>
<td>31/31</td>
<td>29%</td>
<td>10%</td>
<td>42%</td>
<td>81%</td>
</tr>
<tr>
<td>Wang et al60</td>
<td>VTD</td>
<td>38/38</td>
<td>16%</td>
<td>–</td>
<td>71%</td>
<td>87%</td>
</tr>
<tr>
<td>Kaufman et al61</td>
<td>VAD → VTD</td>
<td>34/34</td>
<td>27% CR</td>
<td>32%</td>
<td>35%</td>
<td>94%</td>
</tr>
<tr>
<td>Yoon et al62</td>
<td></td>
<td>55/71</td>
<td>51%</td>
<td>10%</td>
<td>35%</td>
<td>96%</td>
</tr>
<tr>
<td>Richardson et al63</td>
<td>VRD</td>
<td>65/68</td>
<td>38%</td>
<td>30%</td>
<td>25%</td>
<td>100%</td>
</tr>
<tr>
<td>Berenson et al64</td>
<td>VAM</td>
<td>31/35</td>
<td>16% CR</td>
<td>10%</td>
<td>13%</td>
<td>39%</td>
</tr>
<tr>
<td>Bensinger et al65</td>
<td>VCD → VTD</td>
<td>43/44</td>
<td>35%</td>
<td>21%</td>
<td>40%</td>
<td>96%</td>
</tr>
<tr>
<td>Reeder et al66</td>
<td>VCD</td>
<td>33/33</td>
<td>39%</td>
<td>21%</td>
<td>27%</td>
<td>88%</td>
</tr>
<tr>
<td>Knop et al67</td>
<td></td>
<td>100/100</td>
<td>11% CR</td>
<td>–</td>
<td>68%</td>
<td>79</td>
</tr>
<tr>
<td>Barlogie et al68</td>
<td>VTD-PACE</td>
<td>480–480</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NR</td>
</tr>
</tbody>
</table>

Abbreviations: PLD, liposomal doxorubicin; VDD, Velcade, liposomal doxorubicin, dex; TD, thalidomide, dexamethasone; VTD, Velcade, thalidomide, dexamethasone; VAD, vincristine, adriamycin, doxorubicin; VRD, Velcade, revlimid dexamethasone; VAM, velcade, arsenic trioxide, melphalan; VCD, Velcade, cyclophosphamide, thalidomide; VDT-PACE, Velcade, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide.

Figure 7  NF-κB activation pathway. The inhibitor protein IκB, when bound to NF-κB in the cytoplasm, renders NF-κB inactive. A variety of cellular stimuli result in the phosphorylation and ubiquitination of IκB, thereby targeting it for proteasome mediated degradation. Bortezomib, by inhibiting the proteasome, results in increased IκB inhibition of NF-κB, thus resulting in inhibition of tumor growth. Reproduced with permission from Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today. 2003;8(7):307–315.3 Copyright © 2003 Elsevier.
with its involvement in the response to many types of cellular stress. Human NOXA contains one BH3 (Bcl-2 homology 3) domain, which has a high affinity for the antiapoptotic factor Mcl-1. Because Mcl-1 is a target for ubiquitination, proteasome inhibition increases levels of Mcl-1. The induction of NOXA is therefore essential to override high Mcl-1 levels and allow for the activation of the apoptotic machinery in response to bortezomib.\textsuperscript{72} Also, NOXA’s interaction with anti-apoptotic members of the Bcl-2 family causes release of cytochrome c into the cytosol, leading to the activation of caspases and induction of apoptosis (Figure 8).\textsuperscript{73}

Bortezomib induction of NOXA is also seen in melanoma and mantle cell lymphoma cell lines, with antisense NOXA oligonucleotide (but not control) resulting in a decrease in bortezomib induced apoptosis.\textsuperscript{71,74} Of note, apoptosis/NOXA induction is not induced by conventional chemotherapeutic agents but is induced by other proteasome inhibitors (eg, MG132), suggesting a possible class specific effect.\textsuperscript{73,75} To understand why NOXA is preferentially induced in tumor cells, the myriad transcription factors with consensus binding sites at the NOXA promoter were restricted to those that are conserved (as NOXA itself is) across mammalian species and also dysregulated by proteasome inhibition and tumorogenesis. The oncogene c-myc emerged as a candidate mediator of tumor specificity. Indeed, when c-myc levels were decreased by RNA interference, the tumor cell-specific induction of NOXA was abrogated. Exogenous c-myc also increased the sensitivity of nonmalignant cells to proteasome inhibition by bortezomib.\textsuperscript{72}

The interaction of NOXA and c-myc also provides a possible rationale for the encouraging clinical data noted thus far when histone deacetylase (HDAC) inhibitors are combined with bortezomib. The transcriptional activity of c-myc at the NOXA promoter can be favored by chromatin remodeling or modification proteins (including histone acetyl transferases, with acetylated histone H3 being a classical cofactor for myc).\textsuperscript{72} HDAC inhibition is also thought to interfere with the targeting of ubiquinated proteins via the aggresome for eventual autophagy/degradation by the lysosome, an alternate pathway to proteasome-mediated degradation.\textsuperscript{76}

A third possible explanation for the specificity of bortezomib for myeloma cells is based on the unfolded protein response (UPR). Plasma cells have highly developed rough endoplasmic reticulum (ER) and chaperone proteins that enable them to produce vast quantities of antibodies per second. If misfolded proteins accumulate in ER, the UPR signaling pathway is activated through its sensing mechanism IRE1\textsubscript{α}.\textsuperscript{77} The IRE1 kinase, in turn, results in the removal of an intron from the transcription factor XBP1, resulting in a activated ie, spliced form XBP-1.\textsuperscript{78} Interestingly XBP-1 is is highly expressed in plasma cells and is a prerequisite for transformation from antigen selected B cell to plasma cell.

Once the UPR is activated, the unfolded proteins are refolded by upregulation of the chaperone molecules or destroyed through cytosolic 26S proteasomes; otherwise, accumulation of unfolded protein results in apoptosis of the cell (Figure 9). Proteasome inhibition triggers apoptosis by interfering with the UPR pathway, both at the sensing level as well as by preventing destruction of misfolded protein.\textsuperscript{79}

### Pathophysiology and management of bortezomib toxicities

#### Thrombocytopenia

The thrombocytopenia associated with bortezomib therapy has been well characterized. The platelet count drops during Days 1 to 14 and then rapidly recovers to baseline level during Days 15 to 21 (Figure 10). The mean reduction in relapsed/refractory patients is 60% and appears to be independent of the baseline platelet count, the concentration of the monoclonal protein, and bone marrow plasmacytosis. Murine studies demonstrated no cytotoxic effects on megakaryocytes, thus suggesting a mechanism distinct from traditional myelosuppressive chemotherapeutic agents.\textsuperscript{80}
Neuropathy

When the proteasome is inhibited, proteins accumulate in aggresomes at the periphery of cells and then track centrally via microtubules towards the microtubule-organizing center (MTOC). When the distribution of microtubules between polymerized and soluble fractions was compared following the treatment of neuroblastoma and myeloma cells with five proteasome inhibitors, the polymerized fraction increased from 41% to 68% to approximately 55% to 99%, for up to 144 hours after the proteasome inhibitor was removed. Immunofluorescence studies did not reveal microtubule bundles seen with taxanes, suggesting microtubule stabilization occurred by a mechanism different than direct drug binding. Animal models have also found significant mitochondrial and endoplasmic reticulum damage in dorsal root ganglia. Other postulated mechanisms of bortezomib associated neuropathy include mitochondrial dysregulation of calcium homeostasis or dysregulation of growth factors important for neuron survival.

Clinically, it is important to note the baseline rate of neuropathy in patients with relapsed/refractory myeloma. In the phase II SUMMIT and CREST studies with bortezomib, 81% of patients had symptoms by FACT/GOG-Ntx questionnaire and 83% by neurologists’ examination. This likely reflects not only the side effects of prior treatments, but also a manifestation of the disease itself. While the likelihood of developing severe peripheral neuropathy (PN) was more frequent in those patients with baseline neuropathy, the overall occurrence was independent of baseline neuropathy.

In the phase III APEX trial, of the 37% of patients who experienced peripheral neuropathy (PN), 9% had grade \( \geq 3 \). The neuropathy was typically sensory, although 2% of patients did experience motor neuropathy. The neuropathy does appear to be dose related with PN typically occurring by cycle 5 and then reaching a plateau by cycle 8, associated with cumulative bortezomib doses of 26 and 42 mg/m\(^2\) respectively. Based on similar findings in previous studies, the APEX trial also incorporated dose-modification guidelines for PN (see Table 5).

Sixty-eight percent of patients in the APEX study who had dose modification for grade \( \geq 2 \) PN experienced improvement or resolution to baseline in their symptoms at a median of 110 days without any compromise in efficacy. The development of neuropathy was independent of age, prior therapies (including thalidomide and vincristine), and glucose intolerance/diabetes.
A recent publication described a case series of five patients with myeloma who received bortezomib and then developed severe motor involvement. Electrophysiological evaluations showed demyelinating or mixed axonal-demyelinating neuropathy with prominent motor involvement. Cerebrospinal fluid showed albumin-cytological dissociation. Importantly, all four patients treated with either steroids or intravenous immunoglobulin had improved outcomes, suggesting a possible immunologic cause of this neuropathy. Therefore, the development of motor neuropathy merits prompt neurological consultation.

Particularly in the setting of combination therapy, attenuation in the dosing schedule eg, weekly treatment, appears to be associated with significantly less neurotoxicity. For example, the incidence of grade 3 or higher neuropathy with VMP decreased from 14% to 2% with twice weekly vs weekly bortezomib with preliminary outcome data showing no loss in efficacy. Interestingly, patients treated with the combination of the heat shock protein (HSP)-90 inhibitor tanespimycin and bortezomib have not developed Grade 3 PN, suggesting a possible neuroprotective effect of this novel agent. Of note, development/exacerbation of PN has also not been observed to date with the novel proteasome inhibitor carfilzomib, suggesting that this may not be a class specific effect.

Currently there is no proven effective prophylaxis for PN. A variety of agents are used for symptomatic relief of bortezomib associated PN including opioids, tricyclic antidepressants such as nortryptiline, anticonvulsants such as gabapentin, serotonin-norepinephrine reuptake inhibitors such as duloxetine, nonsteroidal anti-inflammatory agents, vitamins, and nutritional supplements such as α-lipoic acid, glutamine, and L-carnitine. However, with recent data suggesting a possible decrease in the efficacy of bortezomib with concomitant vitamin C and other supplements such as green tea, neither the effectiveness in symptom palliation nor the absence of an interaction with bortezomib has been clearly established in randomized clinical trials.

### The future of proteasome inhibition

A protein is first identified to be degraded by the polyubiquitination of lysine residues. The process consists of sequential ubiquitin activation, conjugation, and protein ligation – each catalyzed by E1, E2, and E3 enzymes (Figure 11) – which creates the polyubiquitination chain. It appears that there is a family of small ubiquitin like modifiers such as Nedd8, SUMO, FAT10 and ISG15 that are also able to target proteins for degradation. Each step of this process is therefore a putative therapeutic target. Efforts are underway to evaluate novel agents, with a Nedd8 activating enzyme inhibitor (MLN 4924) already in phase I clinical trials.

Based on the pharmacophore that interacts with the proteasome’s active site, proteasome inhibitors can be divided into five classes: peptide aldehydes, peptide boronates, peptide vinyl sulfones, peptide epoxyketones, and the only nonpeptide group – β lactone inhibitors (Table 6). The peptide aldehydes such as MG-132 are the first class to be studied and while cell permeable, they are not only rapidly oxidized and unstable, but also lack specificity with activity against nonproteasome enzymes such as serine and cysteine proteases.

The peptide boronates were derived by substitution of the aldehyde with boron to increase potency, selectivity, and stability. Bortezomib is currently the only FDA approved proteasome inhibitor. Recently published preclinical data demonstrated activity comparable with bortezomib with another peptide boronate compound, CEP-18770, that is also water-soluble and orally bioavailable. Bortezomib is also being used as a platform for phase I/II studies with numerous novel agents including an anti-IL6 antibody, heat shock protein inhibitors, and epigenetic modulators such as vorinostat or panobinostat. These novel agents may therefore shed light on mechanisms of bortezomib resistance. For example, in two different studies, three patients who were refractory to bortezomib had a response to bortezomib with the addition of a novel agent – either tanespimycin or vorinostat.

<table>
<thead>
<tr>
<th>Severity of peripheral neuropathy signs and symptoms</th>
<th>Modification of dose and regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I (paresthesias and/or loss of reflexes)</td>
<td>No action</td>
</tr>
<tr>
<td>Grade I with pain or Grade 2 (interfering with function but not with activities of daily living)</td>
<td>Reduce bortezomib to 1.0 mg/m²</td>
</tr>
<tr>
<td>Grade 2 with pain or Grade 3 (interfering with activities of daily living)</td>
<td>Withdraw bortezomib therapy until toxicity resolves. When toxicity resolves reintroduce with a reduced dose of bortezomib at 0.7 mg/m² and change treatment schedule to once per week</td>
</tr>
<tr>
<td>Grade 4 (disabling)</td>
<td>Discontinue bortezomib</td>
</tr>
</tbody>
</table>

Grading based on NCI Common Toxicity Criteria CTCAE 3.0
There have been some recent developments in the epoxyketone class of proteasome inhibitors. Epoxomicin is a natural compound initially isolated from an *Actinomycete* strain and found to have antimelanoma activity in preclinical models. Carfilzomib (formerly PR-171; Proteolix®), is a tetrapeptide epoxyketone related to epoxomicin. There are two components of this agent, a peptide portion that binds to the substrate binding pocket(s) of the proteasome with high affinity and an epoxyketone pharmacophore that interacts with the catalytic amino-terminal threonine residue and irreversibly inhibits proteasome activity. Relative to bortezomib, carfilzomib more selectively inhibits the chymotrypsin-like activity of the proteasome with less cross-reactivity at the caspase-like and trypsin-like sites. At doses of 15 mg/m² or greater, there is >80% proteasome inhibition in both red blood cells and peripheral blood mononuclear cells in humans. The ability to give this drug safely on consecutive days allows for sustained proteasome inhibition.

Preliminary data presented at the annual meeting of American Society of Hematology in 2008 from ongoing phase II studies indicate an overall response rate of greater than 50% and 26% in bortezomib-naïve and bortezomib-exposed patients with multiple myeloma, respectively. Cyclic thrombocytopenia was also noted but otherwise, the toxicity profile was different from bortezomib - increased creatinine and possible tumor lysis but no significant neuropathy.

The first member of the β lactone class of proteasome inhibition that received attention was derived from lactacystin, produced by *Streptomyces*. It was highly unstable intracellularly but was more specific than the peptide aldehydes. Salinosporamide A (NPI-0052), a product of a marine actinomycete *Salinispora tropica*, has a bicyclic ring structure similar to lactacystin, but with various substitutions. Preclinical studies have shown that unlike bortezomib, NPI-0052 inhibits all three protease activities of the proteasome. It is also orally bioactive, a more potent inducer of apoptosis in myeloma cells than bortezomib, and demonstrates activity in bortezomib resistant cell lines as well. Preliminary reports from ongoing phase I studies in a variety of tumors indicate that the drug appears to be well tolerated.

The development of the first-in-class proteasome inhibitor bortezomib in multiple myeloma is a paradigm for the optimal interaction between the pharmaceutical industry, academic institutions, and patient advocacy groups. With ever increasing knowledge of the mechanism of action of

---


**Table 7** Classes of proteasome inhibitors

<table>
<thead>
<tr>
<th>Class</th>
<th>Compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peptide aldehydes</td>
<td>MG132</td>
</tr>
<tr>
<td>Peptide boronates</td>
<td>Bortezomib, CEP-18770</td>
</tr>
<tr>
<td>Peptide vinyl sulfones</td>
<td></td>
</tr>
<tr>
<td>Peptide epoxyketones</td>
<td>Epoxomicin, carfilzomib</td>
</tr>
<tr>
<td>β lactone inhibitors</td>
<td>Lactacystin, MLN 519, NPI-0052</td>
</tr>
</tbody>
</table>
this agent, the full therapeutic potential of this growing class of drugs can be realized.

Disclosure

Ajaí Chari and Amitabha Mazumder have both received honoraria related to speakers’ bureau activities from Millennium Pharmaceuticals Inc., The Takeda Oncology Company. Sundar Jagannath has received honoraria related to Advisory Board Consultancy from Millennium Pharmaceuticals Inc., The Takeda Oncology Company.

References


